Fungal Vaccine Design - Creative Biolabs

Creative Biolabs offers comprehensive fungal vaccine design and development services, committed to combating the growing threat of fungal infections. We leverage cutting-edge immunology, molecular biology, and bioinformatics technologies to provide global clients with end-to-end support, from antigen discovery and adjuvant screening to preclinical studies. Our goal is to develop safe, effective, and broadly protective innovative fungal vaccines, accelerating your project's journey from concept to success.

What We Provide for Fungal Vaccine Development?

The key to fungal vaccine R&D is a multi-step process, from selecting the right antigen to validating its safety and efficacy. We offer a comprehensive approach to address these critical stages.

Addressing Antigen Selection Challenges

It is difficult to identify universal antigens capable of inducing a broad-spectrum protective immune response due to the complex and polymorphic nature of fungal pathogens. Additionally, many fungal antigens share similarities with host molecules, which can lead to autoimmune reactions.

Overcoming Lack of Immunogenicity

Fungi possess powerful immune evasion mechanisms that can effectively suppress the host's immune response. Therefore, developing a vaccine that can overcome these mechanisms and generate a strong and lasting cellular and humoral immune response is a significant challenge.

Facilitating Translation from Bench to Clinic

The R&D pipeline for fungal vaccines is relatively small, lacking a mature translational path. We facilitate the smooth transition of laboratory research findings to the preclinical validation stage, addressing regulatory and technical challenges.

Detailed Fungal Vaccine Development Services

Fungal Antigen Discovery and Identification

Using bioinformatics, proteomics, and immunological methods, we screen and identify potential protective antigens from pathogenic fungi.

Vaccine Antigen Design and Engineering

We offer services such as recombinant protein expression, peptide synthesis, and nucleic acid vaccine design tailored to different antigen types (e.g., proteins, polysaccharides).

Vaccine Adjuvant Screening and Optimization

We evaluate various novel adjuvants to enhance vaccine immunogenicity and induce specific types of immune responses (e.g., Th17 immunity).

Immunogenicity Assessment

We use both in vitro cell models and in vivo animal models to comprehensively assess the immunogenicity, safety, and protective efficacy of vaccine candidates.

Preclinical Study Support

Including toxicology studies, pharmacokinetic analysis, and manufacturing process development support.

Table 1. Vaccine strategies developed to treat or prevent fungal infections

Strategy	Potential pros	Potential cons	Design considerations
DC vaccines	Adjuvants that are too toxic to administer to humans can be directly delivered to DCs ex vivo	1. DC vaccination may not be feasible in most populations 2. Costly	1. DC subtype selection 2. Adjuvant selection
Attenuated/killed vaccine	1. Provides numerous antigens specific for the pathogen 2. Protection can be induced independent of CD4þ T cells	Risk of inducing an infection or dysregulated inflammatory response	Attenuation must be irreversible
Recombinant protein (subunit) vaccine	1. Specifically formulated to elicit a protective response 2. Safer than attenuated vaccines, especially in immunosuppressed patients	T-cell responses to antigens may differ as a function of HLA haplotype	Antigen must be present on all strains of the fungus
Conjugate vaccines	1. Can be formulated to induce responses against glycan and/or protein antigens 2. Can be self-adjuvanting 3. Safer than attenuated vaccines in immunosuppressed patients	T-cell responses to antigens may differ as a function of HLA haplotype	Antigen(s) must be present on all strains of the fungus

Platforms & Technologies

A laboratory setting with various vials and scientific equipment, representing a protein expression platform.

Recombinant Protein Expression Platform

Fast and efficient production of high-purity, high-activity fungal protein antigens, utilizing both eukaryotic and prokaryotic expression systems.

A microscopic image of mRNA molecules, representing advanced mRNA technology.

mRNA Vaccine Technology

Our mRNA platform enables in vivo expression of vaccine antigens, offering advantages of rapid development and high immunogenicity.

A scientist analyzing data from single-cell sequencing, representing immunome analysis.

Single-Cell Sequencing and Immunome Analysis

We perform in-depth analysis of immune responses following fungal infection, providing valuable data for antigen and epitope screening.

Diverse Animal Models

We provide various common fungal infection mouse models for in vivo efficacy assessment of vaccines.

Fungal Vaccine Development Process

Project Initiation & Planning

In-depth consultation with the client to define project goals, scope, and key milestones.

Antigen Discovery & Screening

Utilizing bioinformatics and immunological tools to identify potential vaccine antigens from the fungal genome or proteome.

Candidate Vaccine Design & Construction

Based on the selected antigens, we design and construct various vaccine formats, such as recombinant protein vaccines, DNA vaccines, or mRNA vaccines.

In Vitro Immunological Assessment

Testing the immunogenicity of vaccine candidates at the cellular level, including cytokine secretion and antibody generation.

In Vivo Efficacy & Safety Assessment

Vaccinating animal models to evaluate the immune protection efficacy, safety, and dose response.

Optimization & Manufacturing Support

Based on early data, we optimize the vaccine formulation and manufacturing process to support subsequent clinical studies.

Reach out to Creative Biolabs for support!

Why choose Creative Biolabs?

One-Stop Solution

Providing comprehensive services from early research to preclinical support, significantly shortening the R&D cycle.

Advanced Technology Platforms

Our state-of-the-art mRNA, recombinant protein, and bioinformatics platforms ensure the technological leadership of your project.

Customized Services

Offering flexible and tailored solutions to meet the unique needs of each project.

Strict Quality Control

Following ISO 9001 standards to ensure the accuracy and reproducibility of all experimental data.

A laboratory researcher working on a scientific experiment, representing quality control and advanced technology.

Customer Reviews

"The Creative Biolabs team was outstanding on our fungal vaccine project. Their expertise and efficient execution helped us overcome critical technical challenges. We look forward to future collaborations!"

— Dr. Zhang

R&D Director, a biotech company

"Their fungal antigen screening service was highly precise, and we quickly identified several promising candidate antigens. This significantly accelerated our R&D process."

— Maria S.

Professor, a university medical school

"I was highly impressed with the quality of Creative Biolabs' service. The preclinical data they provided was rigorous and reliable, laying a solid foundation for our IND application."

— Mr. Chen

Project Manager, a pharmaceutical company

Case Study

A Self-Adjuvanting Glycopeptide Conjugate Vaccine Against Candidiasis

Project Background: A study was conducted to develop a safe and effective synthetic vaccine for disseminated candidiasis, a severe fungal infection with high mortality. The aim was to create a novel vaccine conjugate that induces a strong protective antibody response without requiring a separate adjuvant unsuitable for human use.

Solution: Researchers synthesized a glycopeptide conjugate vaccine, β-(Man)3-Fba, by combining a mannotriose glycan and a peptide from C. albicans. To enhance immunogenicity for potential human use, they modified the conjugate by coupling it to tetanus toxoid (TT). This new vaccine, β-(Man)3-Fba-TT, was administered to mice with or without adjuvants like alum or MPL.

Result: The study found that the β-(Man)3-Fba-TT conjugate, when administered alone, acted as a self-adjuvanting vaccine. It induced robust antibody responses and a significant isotype switch from IgM to IgG. Immunized mice showed a high degree of protection against a lethal C. albicans challenge, demonstrating increased survival times and a reduced fungal burden in the kidneys. These results confirm that the TT component is sufficient to promote a protective immune response without the need for additional adjuvants.

A chart showing the protective effect of the glycopeptide conjugate vaccine on mice with candidiasis, including survival and fungal burden data.

Protective Effect of Conjugate Vaccine on Mice with Transmitted Candidiasis.
Xin, Hong, et al. "Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis." PloS one 7.4 (2012): e35106. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1371/journal.pone.0035106.

Frequently Asked Questions of Fungal Vaccine Solution

Which fungal pathogens can your fungal vaccine services handle?

We have experience handling a variety of pathogenic fungi, including but not limited to Candida, Aspergillus, Cryptococcus, and Coccidioides.

What is the typical development timeline for a fungal vaccine?

The development timeline varies depending on project complexity and service scope. Generally, it can take several months to a year from antigen discovery to preclinical validation. We work closely with our clients to establish a detailed timeline.

How do you ensure the immunogenicity and safety of the vaccine?

We employ a multi-stage assessment strategy. First, we evaluate immunogenicity through in vitro cell experiments; then, we conduct efficacy tests in animal models; finally, we perform comprehensive toxicology and safety assessments to ensure the vaccine is safe before entering clinical trials.

Can you help us select the appropriate adjuvant?

Yes. We have an extensive adjuvant library and can screen and recommend the most suitable adjuvant based on your antigen characteristics and the desired type of immune response.

If I only have a fungal strain, can you provide a complete solution?

Absolutely. We offer an end-to-end "one-stop" service. You only need to provide the strain, and we can be responsible for all stages from antigen screening, vaccine design, and immunological assessment to preclinical research.

Are you Ready to Begin?

If you have any needs regarding fungal vaccine design and development, please contact us immediately! Our expert team will provide you with professional consultation and support.

Inquire Now

Fungal Vaccine Design Solutions